
The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
Prostaglandin inhibitors and calcium channel blockers were ranked as the top tocolytic therapy options in terms of outcomes of 48-hour delay in delivery, neonatal mortality, respiratory distress syndrome, and maternal side effects, according to a systematic review and network meta-analysis published Oct. 9 in BMJ.






